Biofrontera Q1 Loss Narrows to $0.41, Revenue Climbs 17% to $10.08M
BFRI•Biofrontera posted a first-quarter loss of $0.41 per share versus an expected $0.12 loss, though it narrowed from a $0.47-per-share loss a year earlier. The company generated $10.08 million in revenue, up 17% year-over-year, and improved gross margin to 80% with operating loss trimmed to $4.3 million.
1. Q1 2026 Financial Results
Biofrontera recorded a net loss of $0.41 per share in the first quarter of 2026, improving from a $0.47-per-share loss in Q1 2025. Revenue reached $10.08 million, marking a 17% increase from $8.60 million a year earlier.
2. Revenue Growth Drivers
Revenue growth was driven by stronger sales across the company’s dermatology product lineup, supported by expanded market penetration and heightened prescription volumes. This uptick reflects increased adoption of its flagship therapies in key regions.
3. Margin Expansion and Cost Management
Gross margin expanded to 80% following a strategic supply agreement, enhancing production efficiency. Concurrently, operating loss narrowed to $4.3 million from $4.5 million in the prior-year quarter, reflecting tighter cost controls.
4. Balance Sheet and Ratios
The balance sheet shows a debt-to-equity ratio of 1.27, indicating reliance on leverage for financing. The price-to-earnings ratio remains negative at -1.03 as the company continues investing in growth while working toward sustained profitability.
